SCM
CLDX icon

Silverarc Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Silverarc Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-36,000
Closed -$971K – 85
2022
Q2 		$971K Buy
+36,000
New +$1.05M 0.3% 56

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Silverarc Capital Management's CLDX Position: Q1 2026 in Review

Silverarc Capital Management reduced its Celldex Therapeutics (CLDX) stake by 6.6% in Q1 2026, selling an estimated $346K and leaving 178,378 shares worth $5.66M. The position accounts for 0.58% of the portfolio, ranked #42.

Silverarc Capital Management first reported a position in CLDX in Q4 2020 and has held it in 20 quarters since. The position peaked at $13.9M in Q2 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Silverarc Capital Management held 178,378 shares of Celldex Therapeutics worth $5.66M as of Q1 2026.
  • Silverarc Capital Management sold 12,696 Celldex Therapeutics shares in Q1 2026, an estimated $346K.
  • Celldex Therapeutics made up 0.58% of Silverarc Capital Management's portfolio in Q1 2026, its #42 holding.
  • Silverarc Capital Management first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Silverarc Capital Management's Celldex Therapeutics position peaked at $13.9M in Q2 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.